GILD · 10-Q · 2026Q3 · Full report

Acquisition and Pipeline Expansion

GILEAD SCIENCES, INC. · 2026-10-30 · Importance 71 · Surprise 60 · In source text

During the second quarter of 2026, Gilead completed acquisitions of Arcellx, Tubulis and Ouro Medicines, adding oncology and inflammation assets and capabilities. The filing reports acquired in-process R&D expenses of $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion for Ouro Medicines, net of Lakefront’s shared consideration. The Ouro transaction was conducted with Lakefront, which equally shared the upfront payment and will share contingent milestone payments, subject to customary adjustments. Gilead also announced a definitive agreement to acquire PepStar Therapeutics’ oral IL-23R inhibitor program, including HCXT-2001; closing remains subject to customary conditions.

Key facts

• Gilead announced a definitive agreement to acquire PepStar’s oral IL-23R inhibitor program, including lead asset HCXT-2001; closing is subject to customary conditions. source
• Gilead completed its acquisition of Tubulis, adding next-generation ADC assets including TUB-040 and a platform to develop novel ADCs. source
• Gilead completed its acquisition of Arcellx, building on the collaboration to develop anito-cel for R/R multiple myeloma and adding Arcellx’s D-Domain BCMA binder. source
• Gilead completed its acquisition of Ouro Medicines, adding clinical-stage BCMAxCD3 T-cell engager gamgertamig to its inflammation portfolio; Lakefront shared the upfront payment and will share contingent milestone payments equally, subject to customary adjustments. source

Impact estimates